Park Avenue Securities’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$302K Sell
10,993
-4,371
-28% -$116K ﹤0.01% 1525
2026
Q1
$412K Sell
15,364
-2,506
-14% -$75.1K ﹤0.01% 1189
2025
Q4
$550K Buy
17,870
+1,066
+6% +$33.2K ﹤0.01% 1051
2025
Q3
$515K Buy
16,804
+1,864
+12% +$45.4K ﹤0.01% 1172
2025
Q2
$309K Buy
14,940
+832
+6% +$17.1K ﹤0.01% 1270
2025
Q1
$276K Buy
+14,108
New +$296K ﹤0.01% 1031
2024
Q4
Sell
-10,888
Closed -$265K 1492
2024
Q3
$265K Sell
10,888
-2,902
-21% -$77.6K ﹤0.01% 1233
2024
Q2
$347K Sell
13,790
-461
-3% -$13.1K ﹤0.01% 1130
2024
Q1
$426K Sell
14,251
-1,126
-7% -$33.1K 0.01% 1031
2023
Q4
$490K Sell
15,377
-1,153
-7% -$36.2K 0.01% 919
2023
Q3
$583K Buy
16,530
+1,887
+13% +$71.9K 0.01% 776
2023
Q2
$557K Sell
14,643
-88
-0.6% -$3.51K 0.01% 612
2023
Q1
$556K Buy
14,731
+1,407
+11% +$54.1K 0.01% 586
2022
Q4
$565K Sell
13,324
-6
-0% -$247 0.01% 731
2022
Q3
$428K Buy
13,330
+2,215
+20% +$77.8K 0.01% 768
2022
Q2
$361K Sell
11,115
-36
-0.3% -$1.17K 0.01% 834
2022
Q1
$403K Buy
11,151
+28
+0.3% +$961 0.01% 838
2021
Q4
$440K Buy
11,123
+20
+0.2% +$834 0.01% 765
2021
Q3
$485K Buy
11,103
+321
+3% +$14.4K 0.01% 645
2021
Q2
$440K Buy
10,782
+1,826
+20% +$70.5K 0.01% 687
2021
Q1
$294K Buy
8,956
+1,128
+14% +$42.4K 0.01% 783
2020
Q4
$318K Buy
+7,828
New +$293K 0.01% 663

Other funds holding GMAB

Park Avenue Securities's GMAB Position: Q2 2026 in Review

Park Avenue Securities reduced its Genmab (GMAB) stake by 28% in Q2 2026, selling an estimated $116K and leaving 10,993 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

Park Avenue Securities first reported a position in GMAB in Q4 2020 and has held it in 22 quarters since. The position peaked at $583K in Q3 2023. 77 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Park Avenue Securities held 10,993 shares of Genmab worth $302K as of Q2 2026.
  • Park Avenue Securities sold 4,371 Genmab shares in Q2 2026, an estimated $116K.
  • Genmab made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1525 holding.
  • Park Avenue Securities first reported a position in Genmab in Q4 2020 and has held it in 22 quarters since.
  • Park Avenue Securities's Genmab position peaked at $583K in Q3 2023.
  • 77 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.